Literature DB >> 33276050

Primary Autologous Osteochondral Transfer Shows Superior Long-Term Outcome and Survival Rate Compared With Bone Marrow Stimulation for Large Cystic Osteochondral Lesion of Talus.

Dong Woo Shim1, Kwang Hwan Park2, Jin Woo Lee2, Yun-Jung Yang3, Jucheol Shin2, Seung Hwan Han4.   

Abstract

PURPOSE: To compare the results of bone marrow stimulation (BMS) versus autologous osteochondral transfer (AOT) as primary surgical option for large cystic osteochondral lesion of talus (OLT) and to further distinguish factors associated with clinical failures and overall survival.
METHODS: We retrospectively analyzed patients with symptomatic large cystic OLT (>300 mm3) who underwent either primary BMS or AOT between January 2001 and January 2016 with a minimum follow-up of 36 months. Lesion surface area and volume were measured on magnetic resonance imaging. Clinical outcomes were assessed using pain visual analog scale (VAS), American Orthopaedic Foot and Ankle Society (AOFAS) score, and Foot and Ankle Outcome Score (FAOS). Survival outcomes and factors associated with clinical failures were evaluated using Kaplan-Meier analysis and Cox regression analyses, respectively.
RESULTS: Fifty of the total 853 patients had large cystic OLTs. Thirty-two patients underwent primary BMS, and 18 patients underwent primary AOT. Mean follow-up period was 118 months, and average lesion surface area and volume were 152.8 mm2 and 850.7 mm3, respectively. The primary AOT group showed significantly superior improvements in clinical outcomes compared with the BMS group at last follow-up (P = .001). Fourteen patients in the primary BMS group and 2 patients in the primary AOT group experienced clinical failure. Kaplan-Meier analysis showed a superior survival rate of primary AOT (P = .042). Syndesmosis widening (hazard ratio 12.361; P = .004) and large lesion surface area (hazard ratio 1.011; P = .014) were significant relative risks of clinical failure in the primary BMS group. However, lesion volume showed no significant relationship with clinical failure.
CONCLUSION: Long-term results of primary AOT showed superior clinical improvements and survival rate in treating large cystic OLT. Risk factors for failure in the primary BMS group were large lesion surface area and syndesmosis widening. STUDY
DESIGN: Retrospective comparative study LEVEL OF EVIDENCE: III.
Copyright © 2020 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33276050     DOI: 10.1016/j.arthro.2020.11.038

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  3 in total

1.  Should Arthroscopic Bone Marrow Stimulation Be Used in the Management of Secondary Osteochondral Lesions of the Talus? A Systematic Review.

Authors:  Zaki Arshad; Aiman Aslam; Adil M Iqbal; Maneesh Bhatia
Journal:  Clin Orthop Relat Res       Date:  2022-02-07       Impact factor: 4.755

2.  Management of Bone Cyst of Talar Body by Endoscopic Curettage, Nanofracture, and Bone Graft Substitute.

Authors:  Charles Churk Hang Li; Tun Hing Lui
Journal:  Arthrosc Tech       Date:  2021-07-20

3.  Machine-learning model successfully predicts patients at risk for prolonged postoperative opioid use following elective knee arthroscopy.

Authors:  Yining Lu; Enrico Forlenza; Ryan R Wilbur; Ophelie Lavoie-Gagne; Michael C Fu; Adam B Yanke; Brian J Cole; Nikhil Verma; Brian Forsythe
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-01-09       Impact factor: 4.342

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.